Juno Therapeutics Inc (JUNO) Shares Bought by Mckinley Capital Management LLC Delaware

Mckinley Capital Management LLC Delaware lifted its position in Juno Therapeutics Inc (NASDAQ:JUNO) by 425.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,041 shares of the biopharmaceutical company’s stock after purchasing an additional 25,133 shares during the quarter. Mckinley Capital Management LLC Delaware’s holdings in Juno Therapeutics were worth $1,419,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Juno Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after purchasing an additional 131,864 shares during the period. Capital International Investors bought a new position in Juno Therapeutics in the third quarter valued at $256,339,000. State Street Corp increased its stake in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after acquiring an additional 222,754 shares during the last quarter. Orbimed Advisors LLC increased its stake in Juno Therapeutics by 123.1% in the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock valued at $91,587,000 after acquiring an additional 1,126,400 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in Juno Therapeutics by 162.0% in the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after acquiring an additional 1,229,622 shares during the last quarter. 68.90% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now directly owns 772,082 shares of the company’s stock, valued at $34,558,390.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now directly owns 2,772,679 shares in the company, valued at $128,014,589.43. The disclosure for this sale can be found here. Insiders have sold 473,031 shares of company stock worth $27,031,205 over the last ninety days. Insiders own 15.08% of the company’s stock.

A number of research firms recently commented on JUNO. SunTrust Banks reissued a “hold” rating on shares of Juno Therapeutics in a research note on Monday, January 22nd. Raymond James Financial cut Juno Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday, January 23rd. Leerink Swann cut Juno Therapeutics from an “outperform” rating to a “market perform” rating and increased their target price for the company from $56.00 to $87.00 in a research note on Tuesday, January 23rd. Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th. Finally, Standpoint Research reissued a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $51.20.

Juno Therapeutics Inc (NASDAQ JUNO) opened at $85.82 on Thursday. Juno Therapeutics Inc has a 12 month low of $19.62 and a 12 month high of $86.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/02/15/juno-therapeutics-inc-juno-shares-bought-by-mckinley-capital-management-llc-delaware.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply